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Abstract
Background: The World Health Organization (WHO) recommends oral cholera vaccines (OCVs) as a supplementary tool to
conventional prevention of cholera. Dukoral, a killed whole-cell two-dose OCV, was used in a mass vaccination campaign in
2009 in Zanzibar. Public and private costs of illness (COI) due to endemic cholera and costs of the mass vaccination
campaign were estimated to assess the cost-effectiveness of OCV for this particular campaign from both the health care
provider and the societal perspective.
Methodology/Principal Findings: Public and private COI were obtained from interviews with local experts, with patients
from three outbreaks and from reports and record review. Cost data for the vaccination campaign were collected based on
actual expenditure and planned budget data. A static cohort of 50,000 individuals was examined, including herd protection.
Primary outcome measures were incremental cost-effectiveness ratios (ICER) per death, per case and per disability-adjusted
life-year (DALY) averted. One-way sensitivity and threshold analyses were conducted. The ICER was evaluated with regard to
WHO criteria for cost-effectiveness. Base-case ICERs were USD 750,000 per death averted, USD 6,000 per case averted and
USD 30,000 per DALY averted, without differences between the health care provider and the societal perspective. Threshold
analyses using Shanchol and assuming high incidence and case-fatality rate indicated that the purchase price per course
would have to be as low as USD 1.2 to render the mass vaccination campaign cost-effective from a health care provider
perspective (societal perspective: USD 1.3).
Conclusions/Significance: Based on empirical and site-specific cost and effectiveness data from Zanzibar, the 2009 mass
vaccination campaign was cost-ineffective mainly due to the relatively high OCV purchase price and a relatively low
incidence. However, mass vaccination campaigns in Zanzibar to control endemic cholera may meet criteria for cost-
effectiveness under certain circumstances, especially in high-incidence areas and at OCV prices below USD 1.3.
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Introduction
Despite efforts to improve water supply and sanitation, cholera
still represents a serious public health burden in low- and middle-
income countries. In 2009, more than 220,000 cases and almost
5,000 deaths were reported to the World Health Organization
(WHO) [1]. Due to underreporting and difficulties with surveil-
lance, however, the true burden is likely in the range of 3 million
cases and 100,000 deaths per year [2,3]. A recent review of official
cholera-related morbidity and mortality data from the WHO
Africa region also indicated a potential economic burden of
cholera for families and the health sector [4].
Cholera is an enteric bacterial disease caused by Vibrio cholerae
serogroup O1 or O139 that usually occurs in sudden epidemics.
Main features include acute, profuse watery diarrhea and vomiting
that may lead to dehydration with concurrent electrolyte loss and
eventually death if timely treatment is unavailable. Even though
case-fatality rates (CFRs) may reach 50%, a rate below 1% has
been achieved with proper case management [3,5]. Treatment is
based on prompt rehydration with oral rehydration solution
(ORS) for mild to moderate cases and intravenous (IV) fluids for
severe cases [3]. Antibiotics are recommended for severe, and also
moderate cases, to reduce the duration of episodes and shedding of
infectious V. cholerae [3,6].
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Traditionally, cholera control has been based on prevention
(i.e., adequate water supply, improved sanitation and health
education, and timely treatment). The role of vaccination for
cholera control has recently received increased attention from
public health officials; the WHO recommends oral cholera
vaccines (OCVs) as a supplementary public health tool to
traditional prevention and treatment in endemic and epidemic
settings [7].
A series of research studies, done as part of the Diseases of the
Most Impoverished (DOMI) project coordinated by the Interna-
tional Vaccine Institute (IVI), evaluated the use of OCVs in Asia
and Africa for control of endemic cholera. Private demand for
cholera vaccines was examined through willingness-to-pay studies
[8–11], costs of illness (COI) and mass vaccination data were
collected [12–14], and cost-effectiveness and cost-benefit analyses
were performed [15,16]. Besides the recent article by Poulos et al.
[13], published information about COI due to cholera is lacking
even though patient-level data is needed for economic evaluations
to improve local planning of cholera control.
A joint initiative between the WHO, the IVI and the Ministry of
Health of Zanzibar (MoH) implemented a mass vaccination
campaign with an OCV in two selected cholera-endemic areas of
Zanzibar in 2009. This intervention-cum-research project provided
the opportunity to assess costs of immunization in an endemic
setting. Public COI—defined as fixed and variable costs borne by
the health care provider for setting up and running cholera
treatment centers (CTCs)—were estimated from three outbreaks
that happened in 2009 outside the mass vaccination target
communities. Private direct COI—defined as medical and non-
medical expenses related to patient treatment, and indirect COI—
defined as loss of income borne by patients and their families—
were elicited from a sample of patients admitted to CTCs during
these outbreaks.
This study aims to estimate (i) public and private COI due to
cholera, (ii) costs of an oral cholera mass vaccination campaign,
and (iii) the cost-effectiveness of using OCVs in endemic regions of
Zanzibar from a health care provider and a societal perspective.
Methods
Ethics Statement
Written informed consent was obtained from all study
participants interviewed for private costs of illness. Patients aged
18 years or older were directly interviewed while caregivers were
interviewed if the patient was younger than 18 years. No incentives
were provided to them. The protocol of this study was cleared by
the WHO Research Ethics Review Committee and the MoH
Ethics Committee. All data were handled confidentially and made
anonymous before analysis.
Study Setting
Zanzibar consists of two major islands, Unguja (also named
Zanzibar) and Pemba, which are situated in the Indian Ocean
about 40–60 km off the coast of Tanzania. Zanzibar, a
semiautonomous polity within the United Republic of Tanzania,
consists of five regions, which are subdivided into ten districts, 50
constituencies and 296 Shehias, the latter being the smallest
administrative unit. The main islands cover ,2,557 km2 (Unguja:
,1,651 km2, Pemba ,906 km2). The archipelago is inhabited by
a fast-growing population of ,1.2 million Kiswahili-speaking
Muslim people. Monthly mean per capita expenditure for all
goods and services was TZS 21,000 (,USD 18) in 2004/5 with a
2.1% share for health-related expenditures [17]. Life expectancy
at birth has risen from 47 years in 1988 to 57 years in 2002 [18].
The economy of the islands depends on agriculture (primarily
cloves, coconuts/copra and seaweed), fishing and tourism.
The public health care delivery structure in Zanzibar comprises
two zones, Unguja and Pemba, each with three levels: the primary,
the secondary and the tertiary level. Each zone is headed by a
zonal medical officer. Most of the health care services are provided
at the primary level through Primary Health Care Units (PHCU)
(n = 124). The majority of these units is open during the day to
outpatients and provides basic services. Primary Health Care
Centers (PHCC) (n = 4) are additional facilities on the primary
level; they operate on a 24-hours basis and can admit up to 30
patients. At the secondary level, three district hospitals (only in
Pemba) are operational while the country’s only tertiary level
hospital (Mnazi Mmoja) is located in the capital Stonetown in
Unguja. The top causes of primary- and secondary-level
outpatient visits in 2008 were upper respiratory tract infections
(23%), pneumonia (10%), malaria (10%) and diarrhea (9%) [19].
In recent times, the first cholera outbreak with 411 cases and 51
deaths was reported in 1978 from two fishermen villages in
Zanzibar [20]. More than a dozen outbreaks followed since then
with almost annual episodes since the year 2000. Reyburn et al.
reported an annual incidence of 0.5 cases per 1,000 population
based on a review of routine surveillance data for the years 1997 to
2007 [21], although the true incidence was likely higher due to
underreporting. A seasonal pattern can be observed that follows
the rainy seasons (usually from March to June and from October
to December) during which widespread flooding occurs. Such
deteriorating environmental conditions subsequently expose the
majority of inhabitants on both islands to an increased risk of
waterborne diseases due to the scarcity of safe drinking water
supplies and a generally poor or lacking sanitation infrastructure in
periurban and rural areas.
Based on a consideration of areas of recent cholera activity,
three Shehias per island, adjacent to each other, were selected as
sites for the mass vaccination campaign. In Unguja, the Shehias of
Chumbuni and Karakana in Urban district and Mtopepo in West
district were targeted for the campaign; in Pemba, the Shehias of
Author Summary
Despite efforts to improve water supply and sanitation,
cholera still represents a serious burden in developing
countries. Use of oral cholera vaccines (OCVs) in endemic
and epidemic situations has recently shown a promising
potential to mitigate this burden. To provide local
decision-makers with specific information on OCV use for
cholera control, we assessed the costs and benefits of a
mass vaccination campaign that was conducted in 2009 in
selected endemic areas of Zanzibar. We estimated the
cost-effectiveness of OCVs by collecting health care
provider and household costs of illness from cholera
outbreaks and costs of the mass vaccination campaign
that used the two-dose OCV Dukoral. Cost-effectiveness
was expressed as the incremental costs of the one-off
vaccination program per case, per death and per disability-
adjusted life-year averted, over a three-year time period.
Our model showed that the 2009 mass vaccination
campaign in Zanzibar was not cost-effective, mainly due
to the high OCV price (USD 10) and the relatively low
incidence. Threshold analyses with Shanchol, the second
OCV that is recommended by the WHO, indicated that
mass vaccination in Zanzibar to control endemic cholera
may become cost-effective if done in higher incidence
areas and when OCV prices are reduced to levels below
USD 1.3.
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Kengeja, Mwambe and Shamiani, all located in the rural
southeastern Mkoani district, were chosen.
Dukoral, the only OCV that was pre-qualified by the WHO in
2009, was used in the mass vaccination campaign. Dukoral is a V.
cholerae serogroup O1 whole-cell, killed vaccine containing
recombinant cholera toxin (CT) B subunit protein; it has to be
administered in two doses at least one week apart and requires a
cold chain (2–8uC) [22]. This OCV was originally designed for
immunologically naı¨ve travelers from the north to tropical
countries; it is licensed for use from two years of age and above
and was shown to be 60–90% protective for up to three years [23–
25]. One three-ml vial of Dukoral contains 161011 killed V. cholerae
O1 (biotype classical and El Tor) and 1 mg of the CT B subunit
protein in a suspension. Because the CT B subunit protein is not
gastric acid-fast, the suspension has to be mixed with 1.5 dl of
drinking water and a buffer sachet containing effervescent granules
of sodium bicarbonate before ingestion. Recipients need to fast
one hour before and after ingestion.
Cost Data Collection
Table 1 describes cost components and sources of data collected
for this study. Estimates for public COI were obtained from
interviews with local experts and unvaccinated patients and from
reports and record review. Cost data for the mass vaccination
campaign were collected based on actual expenditure and planned
budget data. Private direct and indirect costs were collected
through interviews done with unvaccinated patients on Pemba. All
costs are reported in 2009 USD from an economic perspective,
based on mid-2009 exchange rates obtained from http://www.
oanda.com/currency/converter/.
Public COI. Usually, CTCs are set up in Zanzibar once a
cholera outbreak has been declared. Any identified person with
acute watery diarrhea will be admitted and treated with IV fluids
(Ringer’s lactate, Hartmann’s solution) and/or ORS, antibiotics
and other drugs (Zinc for children) depending on the dehydration
level. Community help-seeking behavior for cholera in peri-urban
and rural Zanzibar also favors professional treatment in public
health care facilities [26]. Thus, assuming that the majority of
cases that occur during outbreaks are treated in CTCs, this study
collected treatment costs incurred at CTCs to estimate public
COI.
Public COI data from three outbreaks (one from Unguja and
two from Pemba) that happened after the mass vaccination
campaign were collected prospectively and retrospectively from
local health care personnel and experts. All three centers were
visited for an overview of how they were set up and being run.
Fixed COI related to set up and running of centers, but considered
independent of the number of cholera cases, included permanent
material, consumables, transportation and personnel. The latter
included extra (i.e., top up) payments for personnel and
opportunity costs based on functions and salaries of personnel
diverted from other health services. Variable COI incurred for
cholera cases included drugs (resource use obtained from patient
interviews) and material used for patient treatment. Current unit
costs for drugs and material were provided by the chief pharmacist
and the medical store department.
In Unguja, a CTC was opened on September 22, 2009, in
PHCU Chumbuni after a cholera outbreak had been declared in
one of the districts where the mass vaccination was conducted. A
total of 161 patients were admitted over the course of 63 days
before the CTC was closed on November, 29, 2009. Patients were
treated in military tents (at the beginning of the outbreak) and in
premises belonging to the PHCU. During the period while the
CTC was operational, only suspected cholera cases were treated;
patients with other illnesses were sent to adjacent clinics.
The first outbreak on Pemba occurred in Wete district, which is
located between Micheweni district in the north and the Pemban
capital Chake-Chake in the center of the island; the PHCU in
Kiuyu Minungwini was turned into a CTC during 88 days from
May 11, 2009, until August 7, 2009, when 88 patients were
admitted and treated. The second outbreak on Pemba happened
in Micheweni district in the northeast of the island. A school
Table 1. Cost components for cholera collected in Zanzibar, 2009.
Cost components Description Source
Public COI
Fixed costs CTC set up and running including top up
payments and personnel opportunity costs
Questionnaire for zonal and district medical
officers, MoH, NGOs, reports, record review
Variable costs Treatment costs including drugs and material Interview with laboratory-confirmed cases
and health care personnel, questionnaire for
zonal and district medical officers, chief
pharmacist, NGOs
Private COI
Direct Medical, non-medical costs Interview with laboratory-confirmed cases
Indirect Loss of income Interview with laboratory-confirmed cases
Mass vaccination campaign costs
Material Purchase, transport and storage of vaccine,
water and cups
Reports and documents from WHO HQ, WHO
consultants, EPI
WHO consultants Compensation, travel Communication from WHO HQ
Training of vaccinators and social mobilizers Staff compensation, transport, material,
refreshment, venue
Reports and documents from WHO
consultants, EPI
Implementation Staff compensation, transport, material,
communication
Reports and documents from WHO
consultants, EPI
COI: Costs of illness, CTC: Cholera treatment center, MoH: Ministry of Health of Zanzibar, NGO: Non-governmental organization, WHO HQ: World Health Organization
headquarters, EPI: Expanded program on immunization in Zanzibar.
doi:10.1371/journal.pntd.0001844.t001
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adjacent to PHCC Micheweni was turned into a CTC with male
and female and pediatric wards. This center was first open from
June 18, 2009, until August 11, 2009, to admit 349 patients over
the course of 54 days. After another surge in cholera cases, the
center was reopened on August 30, 2009, and run for an
additional 31 days to treat another 32 patients until it was closed
on September 30, 2009.
Private COI. Private COI data were collected with ques-
tionnaires from laboratory-confirmed cholera patients who had
not received cholera vaccines before. A convenience sample of
,100 respondents was selected based on a list of positive cases
from outbreaks kept at the Public Health Laboratory (PHL) in
Chake-Chake, Pemba. Health care providers were then contacted
at the CTC where the patients had been admitted to confirm
details and to contact the patient or the caregiver for an interview.
Based on WHO guidelines [27], a questionnaire was construct-
ed in an adult and a child version to elicit out-of-pocket costs for
cholera cases borne by patients and affected households. After pre-
testing, the questionnaire was administered in face-to-face
interviews to inquire about direct medical and non-medical costs
and indirect costs (i.e., productivity losses to the patient or
caregiver and other household members). Patients aged 18 years
or older were directly interviewed while caregivers were
interviewed if the patient was younger than 18 years. Question-
naires were administered between July and November 2009,
predominantly at respondents’ homes. Questionnaire data were
entered into Microsoft Excel for analysis.
Mass Vaccination Campaign Costs. The mass vaccination
campaign with Dukoral was implemented in the six selected
Shehias in two rounds from January 17 to 26, 2009, and from
February 7 to 16, 2009. Vaccination posts were erected within
easy reach for the targeted population. Posts were run by local
health care workers and villagers and open daily for at least eight
hours. For each round, a total of 21 teams were needed to run the
nine vaccination posts on each island. Each team consisted of six
vaccinators. In addition, eight supervisors were deployed to
Unguja and five to Pemba. The campaign was planned and
implemented by the local Expanded Program on Immunization
(EPI) team and international consultants deployed by the WHO.
Social mobilization was done before and during both rounds by
the MoH Health Promotion Unit.
Cost data on material (purchase, transport and storage of vaccines,
cups and water), training and implementation required for the
campaign were obtained locally from consultants and EPI. Because
the campaign was planned and implemented within the scope of the
research project, raw data were adjusted to exclude costs related to
research. These costs were mostly incurred to train and compensate
people at vaccination posts collecting data with electronic devices for
parallel and subsequent epidemiological studies [28].
Cost-Effectiveness Analysis
Based on a previous study for Bangladesh [29], a model was
developed in Microsoft Excel to estimate the costs and health
effects of a mass vaccination campaign program compared to
standard treatment in CTCs in Zanzibar. A static cohort of 50,000
individuals, reflecting the target population of the 2009 mass
vaccination campaign in Zanzibar, was examined from a health
care provider and a societal perspective. Input parameters for
inclusion in the model were related to vaccine characteristics and
vaccination costs, burden and impact of cholera, and public and
private COI. Private providers were not considered since the
majority of patients would visit public facilities in case of an
outbreak [26]. Indirect effects due to herd protection were also
included in the model since they may play a considerable role in
the overall impact of cholera vaccination [30] and were shown to
make community-based programs in three Asian and one African
setting cost-effective [15].
The base-case model considered costs and effects of a one-time
vaccination program over the duration of protection (i.e., three
years). The annual number of cases without vaccination was
obtained by multiplying the population size times the annualized
cholera incidence obtained from surveillance of diarrhea cases
with laboratory confirmation for cholera in the study area [31].
The annual number of cases under the vaccination program was
derived from adding up direct and indirect effects of the
vaccination program: direct effects were calculated by multiplying
the annual incidence of cases without vaccination with (1 –
protective efficacy among vaccinated people [PE]), coverage, and
population size; indirect effects were calculated by multiplying the
annual incidence of cases without vaccination with (1 – protective
efficacy among unvaccinated people [PEU]), (1 – coverage), and
population size. The variable PEU was derived using the concepts
and a formula from Longini et al. [30] (p. 1778). It calculates what
they refer to as ‘‘indirect vaccine effectiveness’’ = 12(r01/r02),
where r01 is the cholera incidence among unvaccinated people
within a vaccinated sub-region and r02 is the cholera incidence in
an unvaccinated sub-region. In the absence of incidence data
among unvaccinated people from the mass vaccination campaign
area, the incidence rate of 2.34 cases per 1,000 population (after
annualizing, Khatib et al. [31]) calculated from people that resided
in the lowest quintile of surrounding coverage (i.e., ,39%) in a
cluster with a radius of 400 m around vaccinated households was
used as proxy for r02. Khatib et al. showed that herd protection
effects mainly existed within that radius. A longer distance from
the household of the vaccinated person was considered to dilute
the benefit of herd protection. The incidence of 1.29 cases per
1,000 population (after annualizing) among all unvaccinated
people was used as an approximation for r01 [31]. This leads to
a base-case estimate of PEU = 45%.
The number of annual deaths without a vaccination program
was calculated by multiplying the CFR with the annual number of
cases without vaccination. The number of deaths with a
vaccination program was calculated by using the CFR times the
annual number of cases under the vaccination program.
Incremental cost-effectiveness ratios (ICER) calculated as
incremental costs per death, per case and per disability-adjusted
life-year (DALY) averted were used as outcome measures.
Incremental costs were calculated as the difference between costs
of the vaccination program and public COI saved due to the
vaccination from the health care provider perspective. Private
direct COI saved were added in the base-case model adopting the
societal perspective. Private indirect COI saved were not included
in the base-case model [32]. The number of deaths, cases or
DALYs averted was equal to the difference in numbers with and
without the vaccination program. DALYs, which are an aggregate
measure combining morbidity (i.e., years of life lived with
disability) and mortality (years of life lost), were calculated
according to Jeuland et al. [15], assuming no age weighing. Since
no disability weights are available for cholera, the disability weight
of 0.11 for diarrheal diseases [33] was used. Life expectancy at the
average age of onset of 18 years based on patient data was
obtained from WHO life tables for Tanzania [34]. The vaccine
was directly purchased from the manufacturer at a UN price.
Future effects were discounted at a rate of 3.0% for the base case.
Campaign costs were not discounted since the mass campaign
happened over one single year.
Cost-effectiveness was examined according to widely-used
WHO criteria that define an intervention as ‘cost-effective’ if the
Costs and CEA of Cholera Vaccination in Zanzibar
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ICER is less than three times per capita gross domestic product
(GDP) per DALY averted and as ‘highly cost-effective’ if the ICER
is less than per capita GDP per DALY averted [35].
One-way sensitivity analyses were done to estimate the influence
of changes in potentially influential input parameters on model
outcomes. Such key parameters included vaccine purchase price and
delivery costs, protective efficacy (PE, PEU), duration of protection,
incidence, CFR and so forth [15]. Plausible ranges were based on
public health considerations (for vaccine purchase price and delivery
costs, incidence), guidelines (discount rate) and variation for local
data (PE, PEU, CFR, number of ill days, public and private COI).
Base-case values and plausible ranges are presented in Table 2.
Threshold analyses examined at which vaccine purchase price the
intervention would become cost-effective.
Results
Public COI
Table 3 presents the fixed and variable mean public COI at the
three CTC sites. Fixed costs of USD 51 accounted for 85% of
public COI, with mean fixed costs ranging from USD 21 to
USD 88. Direct and indirect human resources costs accounted
Table 2. Model input parameters with plausible ranges.
Parameters Base case Minimum Maximum Assumptions, References
Vaccine costs and characteristics
Vaccine purchase price, 2009 USD per 2 doses 10 2.1 12 Base case: this study; range: 20–120% of
base case based on policymaker and
expert data [36,37]
Vaccine delivery, 2009 USD per 2 dosesa 2.7 1.1 3.2 Base case: this study; range: from USD 0.5
per dose to 120% of base case [15,37]
Protective efficacy among vaccinated people (PE), % 79 47 92 Base case and range (95% CI) [31]
Protective efficacy among unvaccinated people (PEU), % 45 0.0 75 Base case and maximum [31]; minimum:
assuming no indirect protection
Campaign coverage, % 50 NA NA Khatib et al. [31]
Duration of protection, years 3.0 2.0 4.0 Jeuland et al. [15]
Discount rate, % 3.0 0.0 5.0 Constant, for effects [38], no discounting
of costs
Life expectancy at average age of onset, years 45 36 56 Life tables for WHO member states [34];
base case: based on mean age of onset
(18 years) from patient data; range: based
on life expectancy [34] at IQR of age of
onset from patient data
Risk for cholera
Cholera incidence, annual cases per 1,000 population 2.3 0.50 4.0 Base case [31]; range: minimum (Jakarta),
maximum (Beira) [39]
Impact of illness on patients
Case-fatality rate, % 0.86 0.52 1.9 Base case: 14 deaths/1626 cases treated
in CTCs in Unguja and Pemba during
three outbreaks between June 2009 and
April 2010; range: minimum and
maximum (ZMO Unguja); same rate
assumed for vaccinated and unvaccinated
cases
Duration of illness episode, days 5 4 6 Base case: median illness duration from
patient data; range: IQR from patient data
Costs of illness, 2009 USD
Public fixed costs of treatment per episode 51 21 88 Base case: mean from this study (see
Table 3); range: minimum and maximum
from this study (see Table 3)
Public variable costs of treatment per episode 9.2 4.6 18 Base case: mean from this study (see
Table 3); range: 50–200% of base case
[15]
Private direct costs per episodeb 11 4.2 17 Base case: mean from this study (see
Table 4); range: based on IQR from
patient data
Private indirect costs per episodeb 32 4.4 46 Base case: mean from this study (see
Table 4); range: based on IQR from
patient data
aExcluding costs for international consultants (see Table 5);
bEstimates only used in analysis from societal perspective;
CI: Confidence intervals, IQR: Interquartile range, ZMO: Zonal medical officer.
doi:10.1371/journal.pntd.0001844.t002
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for the majority of fixed costs; they were highest in Kiuyu
Minungwini (86%), medium in Micheweni (85%) and lowest in
Chumbuni (80%). The remaining fixed costs were used for
setting up and running the centers. Health care personnel
working in Unguja received higher top up payments than in
Pemba, but the latter were given food to cater for themselves
while on shift. Variable costs of USD 9.2 were mainly driven
by IV fluid use as patients were administered on average
8.8 liters, which cost USD 7.1. Further details on public
variable costs for treatment can be found as supporting
information in Table S1.
Private COI
A total of 95 individuals were interviewed. All but one of the
interviewed patients had been admitted at the CTC at Micheweni
PHCC. Total direct and indirect mean private COI amounted to
USD 43, with almost three-fourth (USD 32) being indirect costs (i.e.,
productivity losses to the patient or caregiver and other household
members) (Table 4). Among direct costs, which amounted to USD
11, feeding the patient at the CTC accounted for the biggest share
(USD 8.3, 19% of total costs). Other direct costs, incurred for
treatment (mainly for plastic sheets needed to cover cots), transport
and communication, were reported each by less than 3%.
Mass Vaccination Campaign Costs
Total mass vaccination campaign costs amounted to USD
760,000, with USD 510,000 (68%) spent on vaccine purchase and
USD 240,000 (32%) on delivery (Table 5). The vaccine was
purchased from SBL Vaccin AB, Sweden, at a price of USD 10
per course (2 doses). Delivery costs comprised transport of the
vaccine from Stockholm to Zanzibar and procurement of cups and
water required for the buffer solution (6.0% of campaign costs), the
work of two experienced international consultants (14%), training
of locally recruited implementers (1.3%) and the implementation
Table 3. Public costs of illness for cholera, Zanzibar, 2009.
Description 2009 USD %
Fixed costsa 51 85
CTC at PHCU Chumbuni (Unguja) 88 100
Permanent material Beds, canvas, ropes, basins, buckets, further utensils 6.4 7.2
Consumables Water, detergent, kerosene 2.5 2.9
Transport Fuel for DHMT cars 8.7 9.9
Personnel Top up payments 27 31
Personnel diverted from other health care services Opportunity costs based on functions and official salaries of health care
workers deployed to CTCs
43 49
CTC at PHCC Micheweni (Pemba) 21 100
Permanent material Water drum 0.0 0.0
Consumables Detergent, kerosene 1.2 5.6
Transport Fuel for DHMT cars 1.9 9.4
Personnel Top up payments and food allowance 6.0 29
Personnel diverted from other health care services Opportunity costs based on functions and official salaries of health care
workers deployed to CTCs
12 56
CTC at PHCU Kiuyu Minungwini (Pemba) 46 100
Permanent material Water tank, cooking utensils etc 1.9 4.1
Consumables Chlorinated lime 1.7 3.8
Transport Car use 2.6 5.8
Personnel Top up payments and food allowance 14 30
Personnel diverted from other health care services Opportunity costs based on functions and official salaries of health care
workers deployed to CTCs
26 57
Variable costsb 9.2 15
Total costs 61 100
aMean costs per treated patient at each CTC;
bMean costs per treated patient from patient interviews (n = 95), including drugs and material, see supporting information (Table S1) for more details;
CTC: Cholera treatment center, PHCU: Primary health care unit, PHCC: Primary health care center, DHMT: District health management team.
doi:10.1371/journal.pntd.0001844.t003
Table 4. Private direct and indirect costs of illness for cholera,
Zanzibar, 2009.
2009 USDa %
Direct costs 11 (9.1) 27
Medical 1.2 (1.6) 2.8
Food 8.3 (6.6) 19
Transport 1.2 (2.7) 2.9
Communication 0.65 (1.4) 1.5
Indirect costs (i.e., lost productivity) 32 (35) 73
Total costs 43 (40) 100
aMean costs (standard deviation in brackets) per treated patient from patient
interviews (n = 95).
doi:10.1371/journal.pntd.0001844.t004
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(social mobilization and vaccination) itself (10%). More details on
delivery costs are presented as supporting information in Table S2.
At a vaccine purchase price of USD 10 per course, the
estimated total costs per fully immunized individual amounted to
USD 30, with mean costs per vaccine course of USD 21 and mean
costs for delivery of USD 9.7. The latter amounted to USD 5.3
after exclusion of services from international consultants, lowering
the overall total costs per fully immunized individual to USD 26.
Mean costs were adjusted for actual coverage of 50%, relating to
23,921 fully immunized individuals out of a population denom-
inator of 48,178 used in the analysis by Khatib et al. [31].
Cost-Effectiveness Analysis
Base-Case Results. Table 6 presents the results of the cost-
effectiveness analysis from the health care provider perspective
using base-case parameter estimates obtained from primary and
secondary data sources from Zanzibar. Annual costs to immunize
50,000 people, if the OCVs cost USD 10 per course, were USD
430,000 assuming one campaign per three years at a cost of USD
1.3 million. Annual public COI averted by vaccination amounted
to USD 4,000. Incremental costs, the difference between total
annual costs (i.e., vaccination program and public COI) with and
without vaccination, amounted to USD 430,000. ICERs were
USD 750,000 per death averted, USD 6,500 per case averted and
USD 30,000 per DALY averted.
Logistical on-site support from the WHO headquarters was
provided since the campaign was conducted within a research
project that aimed to assess also epidemiological and socio-
behavioral aspects of OCV use in endemic settings. Thus, costs
incurred for international consultants were excluded from the
analysis on the assumption that the campaign would also have
been possible without intensive external help.
The predicted ICER was much greater than three times the per
capita GDP for Tanzania (USD 1,500 in 2009) per DALY averted
[40], suggesting that mass immunization with OCV in Zanzibar
was not cost-effective. Even if the OCV was donated to the
government at no cost, the vaccination would still cost more than
the avoided public COI due to the delivery costs; and the ICER
would be USD 6,000 per DALY averted.
Compared to the health care provider perspective, key
outcomes of the cost-effectiveness analysis from the societal
perspective (Table S3), which included private direct COI, did
not differ from each other.
Sensitivity Analyses. One-way sensitivity analyses from the
health care provider perspective were performed with input
parameters presented in Table 2. This analysis does not account
for the effects of non-linearity and interactions between uncertain
parameters as it varies parameters one at-a-time while keeping
other parameters at base-case values, and the ranges specified for
each parameter may not reflect equivalent ranges of uncertainty
[41]. Varying base-case values over plausible ranges helped to
estimate the influence of parameters on the ICER per DALY
averted (see Figure S1), and per death (Figure S2) and case (Figure
S3) averted. The most influential parameters on the ICER per
DALY averted were incidence, CFR, discount rate and vaccine
purchase price.
In the absence of herd protection (i.e., if PEU = 0%), the ICER
per DALY amounted to USD 48,000; and when assuming a herd
protection rate as achieved in Zanzibar (PEU = 75%), the ICER of
USD 24,000 still by far exceeded the criterion of USD 1,500,
below which the intervention was defined as cost-effective.
Acknowledging that the incidence would have been higher than
the base-case estimate used in the model if there had been no
OCV campaign at all in Zanzibar, an annual incidence of 4.0
cases per 1,000 population from Beira was used as an upper bound
in the sensitivity analysis. Even though the ICER was reduced to
USD 18,000 per DALY averted at this incidence rate, the
campaign was still cost-ineffective.
Threshold Analyses. Another two-dose OCV was licensed
for use in India in 2009. Shanchol (Shanta Biotechnics,
Hyderabad, India) is a bivalent variant of Dukoral, containing
killed V. cholerae O1 and O139, but no CT B subunit. It has
recently been pre-qualified by the WHO for UN use; at its current
price of USD 1.9 per dose to the public sector, it may become an
attractive alternative for future OCV campaigns [22]. Analysis
from three years of follow-up of a randomized controlled trial from
Kolkata, India, showed that Shanchol has a protective efficacy
(PE) of 66% across all age groups [42]. Repetition of the OCV
campaign in Zanzibar with Shanchol at USD 3.7 per course and
PE = 66%—ceteris paribus—would reduce the ICER to USD
16,000 per DALY averted from the health care provider and
the societal perspectives.
In addition, changing vaccine delivery costs to USD 1.1 (being
the minimum level used in this study), cholera incidence to 4.0
cases per 1,000 population and CFR to 1.9% (both parameters
being at the maximum level) would further reduce the ICER to
USD 3,300 per DALY averted from both perspectives. Based on
these assumptions the purchase price of Shanchol per course
would have to be as low as USD 1.2 to render the mass
vaccination campaign cost-effective from a health care provider
perspective (or USD 1.3 from a societal perspective).
Discussion
This study estimated public and private COI due to endemic
cholera in Zanzibar and costs of the 2009 mass vaccination
campaign to assess cost-effectiveness from a health care provider
and a societal perspective. The analysis presented here suggests
that COI averted by a mass vaccination campaign with an OCV
were negligible to the public health sector and the society and that
such an intervention was not cost-effective based on the stated
assumptions. However, mass vaccination campaigns in Zanzibar
to control endemic cholera may meet WHO criteria for cost-
effectiveness under certain circumstances of highly optimistic
assumptions about vaccine purchase price, delivery costs,
incidence and CFR. It should also be noted that the ICERs do
not explicitly account for the indirect COI and the societal value of
Table 5. Costs of a mass oral cholera vaccination campaign,
Zanzibar, 2009.
Totala Meanb %
Vaccine (purchase price USD 10 per course) 510,000 21 68
Deliveryc 240,000 9.7 32
Vaccine transport, storage, water and cups 45,000 1.8 6.0
International consultants 110,000 4.4 14
Training 9,500 0.38 1.3
Implementation 78,000 3.2 10
Total costs 760,000 30 100
aTotal costs (2009 USD) to vaccinate a target population of 49,980 people;
bMean costs (2009 USD) per fully immunized individual based on actual
coverage (50%);
cBased on actual expenditure or planned budget data from 2009 mass
vaccination campaign, see supporting information (Table S2) for more details.
doi:10.1371/journal.pntd.0001844.t005
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prevented premature deaths, which are implicitly captured in the
effectiveness in terms of averted DALYs.
Private costs were higher than in Beira, Mozambique [13],
where Dukoral had also been used in a mass campaign in endemic
settings. Although mean public and private COI of USD 104 per
episode were higher than the USD 47 for hospitalized cases in
Beira, the mass vaccination campaign was not cost-effective in
Zanzibar.
Relative costs for the vaccine and for delivery were comparable
to findings from two campaigns in Vietnam with the bivalent
Vietnamese OCV where this ratio was 25 vs. 75% in 1997 [43]
and 21 vs. 79% in 1998 [12], respectively. However, due to the
high vaccine purchase price, mean costs per fully immunized
individual of USD 21 were much higher than previously reported
costs of USD 0.5 to 10 from Sudanese refugee settlements in
northern Uganda (1997) [44] and of USD 2.1 from Beira,
Mozambique (2003), where the vaccine was provided free of
charge [14].
Mean costs for delivery of USD 5.3 (after exclusion of costs
related to international consultants) tended to be more in the range
of previous campaigns in other regions; costs in the Zanzibar
campaign were between the USD 3.3 reported for Darfur, Sudan
(2004) [45], and the USD 8.6 reported for the mass immunization
campaign in post-tsunami Aceh, Indonesia (2005) [46].
ICERs were well above any results reported for previous cholera
mass vaccination campaigns [15,29,47–50]. The main reason why
mass vaccination with Dukoral was cost-ineffective in Zanzibar
may be due to using an expensive OCV in a relatively low
incidence setting. Another reason may be that the present model
used local data on costs of immunization. Other cost-effectiveness
models that were not based on locally available data generally
assumed much lower immunization costs, using (subsidized)
vaccine prices of ,USD 1 and delivery costs of ,USD 1 per
course; this made them propose that vaccination is economically
more viable than standard treatment [15].
Also noteworthy in contrast to Jeuland et al. [15] is the finding
that the inclusion of indirect effects in the model did not make the
intervention cost-effective. The ICERs per DALY averted for both
the base-case and the maximum estimate for herd protection were
well above the WHO criterion for cost-effectiveness.
Limitations
This study has several limitations. First, due to limited data
availability, this cost-effectiveness analysis assessed the value for
money of a population-wide OCV campaign and not of a targeted
approach for high-risk or specific age groups, which might make
the intervention cost-effective as shown by Jeuland et al. for school-
based programs in Kolkata and Beira [15]. However, threshold
analyses using Shanchol indicated that scenarios targeting high-
risk groups may become cost-effective in Zanzibar if the OCV was
procured at a price below USD 1.3, a level acceptable by many
public health policy makers in Asia [36].
Second, it may be argued that the assumption of a preference
for health facilities during a cholera outbreak may not necessarily
reflect actual behavior as patients could also be negatively
influenced by accessibility problems. Local observation and
informal interviews, however, support this assumption, and the
dense primary health care system reduces transport issues
(according to the 2004/5 household budget survey, mean distance
to a health care center in the urban and rural area was 0.4 and
1.7 km, respectively [17]) and because treatment for diarrhea is
free.
Table 6. Key outcomes from model of mass oral cholera vaccination (health care provider perspective) in Zanzibar, 2009.
No vaccination Vaccination Difference
Effects
Annual number of cases 110 41 69
Annual number of deaths 0.92 0.35 0.57
Annual number of YLD averted 0.09
Annual number of YLL averted 14
Annual number of DALY averted 14
Total number of DALY averted over duration of protection 40
Costs of outcome indicators, 2009 USD
Annual costs of vaccination programa 0 430,000 2430,000
Annual public costs of illness 6,500 2,500 4,000
Annual costs of treatment and vaccination program 6,500 440,000 2430,000
Costs per death averted with vaccine 760,000
Costs per case averted with vaccine 6,600
Costs per DALY averted with vaccine 31,000
Incremental costs and cost-effectiveness ratios (ICER), 2009 USD
Incremental costsb 430,000
ICER (death): Incremental costs/death averted 750,000
ICER (case): Incremental costs/case averted 6,500
ICER (DALY): Incremental costs/DALY averted 30,000
Base-case results from population of 50,000, with 3% annual discounting of effects.
aCosts for international consultants excluded;
bCosts of vaccination program minus public COI averted by vaccination (cost savings);
YLD: Years of life lived with disability, YLL: Years of life lost, DALY: Disability-adjusted life-year, ICER: Incremental cost-effectiveness ratio.
doi:10.1371/journal.pntd.0001844.t006
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Third, non-diarrhea patients were usually not treated or
admitted by their local public health care facility during the time
it operated as a CTC. People seeking treatment for non-diarrheal
diseases (e.g., for malaria) during an ongoing cholera outbreak will
have to bear extra direct and indirect costs related to additional
travel or potential serious complications due to delayed treatment.
These additional costs have not been included in the cost-
effectiveness analysis due to a lack of relevant data; future studies
in the area are advised to collect estimates on the costs of patients
who are not able to get treatment at their usual center to assess the
relevance of this ‘crowding out’ effect on cost-effectiveness.
Fourth, the ICER might have been overestimated because
waning has not been included in the estimate for PE. Jeuland et al.
have adjusted their estimate in year 3 down by 17% [15].
However, since this represents a limited effect, and since sensitivity
analysis included a minimum PE of 47%, omission of waning as
input parameter in the model is likely to have only a limited effect.
Fifth, threshold analysis for Shanchol did not consider potential
savings due to the probably easier and faster administration of this
new vaccine by oral syringe; this may have resulted in more
favorable cost-effectiveness, but any beneficial effect will likely be
limited because delivery costs influenced the ICER only to a small
extent.
Sixth, even though uncertainty in input parameters was
considered in one-way sensitivity analyses, no full probabilistic
uncertainty and sensitivity analysis was conducted which would
provide a more complete picture of the distribution of possible
outcomes and may find that some combinations of assumptions
lead to greater cost-effectiveness than identified in the one-way
sensitivity analysis [38].
Finally, a cost-benefit analysis may provide more useful
information to local policy makers than a cost-effectiveness
analysis because it explicitly characterizes the monetary value of
prevented disease. However, willingness-to-pay data were not
available for Zanzibar and contingent valuation exercises were
beyond the scope of this study. Also, since campaign coverage with
the free OCV in Zanzibar was merely 50% overall [31] and the
community demanded a free vaccine [51], not making the OCV
available for free in future campaigns would further jeopardize
vaccine effectiveness and thus make such a program even less
economical.
Conclusions
The analysis presented here suggests that costs averted by a
mass vaccination campaign with an OCV in endemic areas of
Zanzibar were negligible when compared to standard treatment in
decentralized cholera treatment centers. Mass vaccination was not
cost-effective based on empirical data and the stated assumptions,
mainly due to the relatively high purchase price and the relatively
low cholera incidence in Zanzibar. However, mass vaccination
campaigns in Zanzibar for endemic cholera control may meet
WHO criteria for cost-effectiveness under certain circumstances,
especially in high-incidence areas and when OCV prices are
reduced to levels below USD 1.3.
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